Vraylar (Cariprazine): Uses, Benefits, Side Effects, and Dosing

Vraylar is often called an antipsychotic, but it is also prescribed for bipolar depression and as an add-on for major depression. Being offered it does not mean you have schizophrenia. Here is what the current FDA label supports, how much it tends to help, and the side effect worth knowing by name: akathisia.

What to know

• Vraylar (cariprazine) has four FDA-approved uses: schizophrenia in adults and adolescents 13 and older; manic or mixed episodes of bipolar I disorder in adults and children 10 and older; bipolar I depression in adults; and as an add-on to an antidepressant for major depressive disorder in adults. The pediatric approvals were added in December 2025.[1]
• It is a once-daily capsule that can be taken with or without food, in strengths from 0.5 mg to 6 mg. The right dose depends on the condition and age.[1]
• Akathisia is the side effect to know. In the label’s bipolar depression trials and its two six-week add-on depression trials, inner restlessness was reported by up to about 10% of people on higher doses, compared with 2% on placebo.[1]
• Effects can build slowly. Cariprazine and its long-lasting active metabolite take weeks to reach steady levels, so side effects can appear or change weeks after a dose change.[1,13]
• Maintenance evidence differs by condition. It lowered relapse in stabilized adults with schizophrenia, but a 2024 bipolar I maintenance trial did not show a prevention benefit.[10,12]
• A generic is not currently on the market. Approved generic cariprazine products were listed by the FDA as discontinued as of September 30, 2026.[33]

Zoom

Why the reason for treatment matters

Vraylar is the brand name for cariprazine, a prescription medicine used for schizophrenia, certain episodes of bipolar I disorder, and as an add-on to an antidepressant for major depression. It changes how some brain signals act at their receiving sites. The right use and dose depend on the condition being treated and the person’s age.[1]

Being offered a medicine called an antipsychotic does not, by itself, mean you have schizophrenia. Medicines in this class can serve several purposes. You deserve to know which symptoms your prescriber hopes to help, what improvement would look like, and what would make the plan worth changing.

Vraylar at a glance

• What it is: A once-daily capsule in the atypical antipsychotic class.
• Why it may help: Its clinical benefits have been tested in specific mood and psychotic disorders.
• What deserves special attention: Inner restlessness, movement problems, sleep changes, and weight or metabolic changes.
• Why follow-up matters: Some effects build slowly and may appear weeks after starting or changing a dose.
• What treatment should improve: Symptoms and the daily life that matters to you, with a side-effect burden you can manage.[1,2]

This guide supports a treatment discussion. It does not supply a personal dosing, switching, or stopping plan.

What is Vraylar (cariprazine)?

Cariprazine is the active ingredient. Vraylar is its U.S. brand name. It is taken by mouth and is not a long-acting injection. The available capsule strengths include 0.5, 0.75, 1.5, 3, 4.5, and 6 milligrams. The smaller strengths have specific roles; a new capsule strength does not mean it is an effective stand-alone dose for every condition.[1]

An SSRI antidepressant mainly changes the handling of serotonin between nerve cells. Cariprazine acts directly at several receptors, or receiving sites, for dopamine and serotonin. It is not a stimulant or a medicine whose main purpose is to make someone sleep.[1,14]

People sometimes call it a mood stabilizer because it can help certain bipolar symptoms. That phrase can hide important differences. A medicine that treats a manic or depressed episode does not automatically have the same evidence for preventing the next episode. Ask what role it serves in your whole plan.[12]

What is Vraylar used for? FDA-approved uses

U.S. approval applies to a particular condition, treatment role, and age group. As of this review, the current Vraylar label includes the following uses.[1,3]

The pediatric schizophrenia and mania approvals were added in December 2025. They do not extend to childhood bipolar depression or childhood major depression. Vraylar is also not approved for irritability associated with autism.[1,3]

Vraylar for schizophrenia

Schizophrenia can involve hallucinations, strongly held beliefs that others do not share, disorganized thinking, low motivation, and difficulty with everyday tasks. These experiences vary. A person may need help with one group of symptoms much more than another.[35]

For someone hearing distressing voices, a useful goal might be less distress and fewer interruptions. For someone whose thoughts feel hard to organize, it might be following a conversation or managing a morning routine. Medication is usually one part of care alongside practical, social, and psychological support.[35]

Vraylar for bipolar I mania or mixed episodes

Mania is more than having a good day or feeling energetic. It can involve a major change in sleep need, energy, speech, judgment, or behavior. A person may feel unusually confident, irritable, or driven. Severe symptoms can make urgent care necessary.[36]

Vraylar has evidence for treating acute manic or mixed episodes. However, feeling both anxious and depressed does not automatically establish a mixed bipolar episode. New restlessness after a medication change also needs its own assessment. Describe the timing and symptoms rather than deciding on the cause alone.[9]

Vraylar for bipolar I depression

Vraylar can be used to treat a depressive episode in adults with bipolar I disorder. This is different from its use in major depression, where its approved role is as an add-on to an antidepressant.[1]

Bipolar II is a different diagnostic history. Results from bipolar I trials cannot simply be carried over to bipolar II. An early trial enrolling people with either type did not show a clear overall benefit over placebo. That does not prove that no person with bipolar II could benefit, but it does limit what can honestly be promised.[22]

Vraylar as an add-on for major depression

Sometimes an antidepressant helps only partly. Adding Vraylar is one option a clinician may consider after reviewing diagnosis, dose, duration, side effects, and other reasons symptoms persist. Its FDA-approved MDD role is alongside an antidepressant, not as a replacement taken alone.[1,4]

An add-on can also add burdens, including another cost and more side effects. Ask why adding a medicine fits your situation better than other reasonable next steps. The term treatment-resistant depression has different definitions; a Vraylar prescription does not mean that every other option has failed.

How does Vraylar work?

Nerve cells communicate through chemical messengers. A receptor is one place where a messenger can attach and affect a cell’s activity. Dopamine and serotonin are involved in many brain functions. They are not simply good or bad chemicals, and there is no single chemical reading that explains a person’s whole illness.

An agonist activates a receptor. An antagonist blocks activation by another substance. A partial agonist activates a receptor but produces a smaller response than a full agonist in a given testing system. Its effect also depends on the surrounding conditions.[14]

Imagine a door that a person can open only partway while also occupying the entrance. That gives a rough sense of partial activation and competition at a receptor. The analogy stops there: real brain networks are much more complex, and the medicine does not sense exactly how much dopamine each area needs.

Cariprazine acts as a partial agonist at dopamine D3 and D2 receptors and serotonin 5-HT1A receptors. It also blocks serotonin 5-HT2A receptors. Laboratory work shows stronger binding to D3 than D2, and brain imaging studies support D3 engagement in people.[1,14,15]

D3 receptors have drawn interest because of their possible role in reward and motivation. That interest is a reason to do studies, not proof that Vraylar will restore pleasure, sharpen memory, or improve attention for everyone. The FDA label states that its exact therapeutic mechanism is unknown.[1]

How well does Vraylar work?

The most useful answer combines research with what happens in your own life. A trial average cannot predict whether you will respond. Some people improve substantially, some improve partly, and some stop because the benefit is too small or the side effects too difficult.

In a six-week schizophrenia trial with 732 randomized adults, cariprazine improved symptom scores more than placebo. The study also included risperidone to help show that the trial could detect a working treatment. It was not designed to declare one medicine the best choice for every patient.[8]

In a three-week mania trial with 497 randomized adults, both tested cariprazine dose ranges improved mania more than placebo. The higher range did not produce a larger average improvement. Some research doses exceeded today’s recommended maximum and should not be copied into personal treatment.[9]

For bipolar I depression, several studies found an average benefit over placebo. In one six-week trial, both 1.5 and 3 mg helped the main depression score. In another, 1.5 mg met the primary statistical test but 3 mg did not. These results are one reason a larger dose should not be assumed to work better.[6,7,40]

For add-on treatment of MDD, a 2023 trial found that about 44 in 100 people taking 1.5 mg plus their antidepressant met the study’s response threshold, compared with about 35 in 100 taking placebo plus their antidepressant. Response meant a major reduction in the rating score; it did not mean every symptom had disappeared. Remission rates were not significantly different.[4]

Another large MDD trial found no significant advantage for either tested dose over placebo. Positive and negative studies both belong in the discussion. The overall evidence supports an approved treatment option, not a promise that adding it will solve depression.[5]

What about motivation, pleasure, and thinking?

A 26-week study compared cariprazine with risperidone in 461 adults with stable schizophrenia and persistent, predominant negative symptoms. These include reduced expression, speech, interest, and drive. Cariprazine did better on the main negative-symptom score, with a modest average difference.[11]

That result does not establish a general treatment for low motivation. Depression, poor sleep, sedation, ongoing psychosis, substance use, and life circumstances can all affect drive. They require different questions.

Analyses of bipolar I depression trials have also explored anhedonia, the loss of interest or pleasure. Some findings favor cariprazine. These were analyses of existing trial data, not a new approval for anhedonia as a stand-alone condition. They cannot tell whether a particular person will regain pleasure because of D3 activity.[24]

Does it prevent future episodes?

For schizophrenia, a study in adults who first became stable on cariprazine found fewer relapses among those who continued it than among those switched to placebo. About 25% versus 48% relapsed during follow-up of up to 72 weeks. Because only selected stable patients entered this part of the study, the result does not describe every person starting treatment.[10]

The bipolar maintenance evidence is different. In a 2024 study, 440 stable adults were randomized to cariprazine or placebo for up to 39 weeks. Neither cariprazine dose significantly improved relapse prevention. The low placebo relapse rate makes interpretation harder, but the trial did not establish a prevention benefit.[12]

This is a reason to ask about your long-term plan, not a reason to stop a helpful medicine yourself. The team should explain what is treating the current episode and what is supporting future stability.

How long does Vraylar take to work?

The body changes cariprazine into active breakdown products, called metabolites. They continue to act after the original medicine has been processed. One, called DDCAR, can remain for a long time.[13]

This creates a delay between a change in the prescription and the full change in exposure. You may notice something early, while other effects build later. Symptoms after a recent increase can still be medication-related even if the first few days seemed fine.

The time until drug levels settle is not the same as the time until a person feels better. It is also not a deadline for recovery. Trials for mania often assessed outcomes after three weeks; many depression trials used six-week outcomes. Individual care needs earlier safety checks as well as a longer view of benefit.[4,9,13]

This is a monitoring guide, not a guaranteed timetable. Severe agitation, unsafe behavior, worsening suicidal thoughts, or an inability to eat or drink should not wait for the medicine to have more time.

Vraylar dosing and everyday use

Vraylar is taken once daily, with or without food. Choose a routine that follows the prescription. If it affects sleep or alertness, ask whether changing the time of day would help. Do not take extra doses to move the schedule.[2]

The table below shows standard labeled doses. Interactions and individual circumstances can require different instructions. These are reference ranges, not directions for increasing your own dose.[1]

The labeled schedule differs by use. For adult bipolar depression and add-on MDD treatment, an increase to 3 mg may occur on day 15, depending on response and tolerance. Faster increases in MDD trials produced more adverse reactions. Your prescriber may choose to wait longer.[1,39]

For one missed dose, take it when remembered unless the next dose is nearly due. In that case, skip it. Do not double up. If several doses were missed, ask the prescriber or pharmacist how to resume. A long-lasting medicine still needs a clear schedule.[2]

Changing or stopping treatment can bring back the original illness. Symptoms after a change can also reflect physical adaptation or a new problem; they do not automatically mean addiction. Cariprazine-specific withdrawal evidence is limited. Switching and tapering need an individual plan, especially because active drug persists for weeks. This guide does not give a universal taper.[1,13]

Ask the pharmacist before opening, crushing, or altering a capsule. The label does not provide a routine sprinkle method. If swallowing is hard, ask for a safe alternative instead of improvising. Keep capsules away from children and pets, excess heat, and moisture.[1,2]

Akathisia: the Vraylar side effect to know by name

Akathisia is an uncomfortable inner need to move. You may pace, rock, shift your feet, or feel unable to sit through dinner. Some people feel intense inner distress without much visible movement. It can be mistaken for anxiety, impatience, or worsening illness.[16]

Tell the prescriber when it began, whether it followed a new medicine or dose change, and what it stops you from doing. A useful description is: “I feel driven to move, and sitting still makes it worse.” That describes a symptom without assuming a diagnosis.

Contact the treatment team promptly for new or worsening restlessness, especially when it is hard to tolerate. Seek urgent help if distress becomes severe or you feel unable to stay safe. Do not add someone else’s medicine, alcohol, or sedatives to quiet it.

In the label’s adult bipolar-depression trials, akathisia was reported by 2% on placebo, 6% on 1.5 mg, and 10% on 3 mg. In two six-week add-on MDD trials, the corresponding rates were 2%, 7%, and 10%. These are different study groups, not a prediction of your own risk.[1]

The team may review the dose, timing, other medicines, and whether a different treatment fits better. The goal is to take the problem seriously while also protecting the benefits of treatment.

Other Vraylar side effects and when to seek help

Nausea, constipation, tiredness, sleepiness, trouble sleeping, dizziness, and appetite changes can occur. Movement effects may include tremor or stiffness. Record what happens and how much it interferes with life. A symptom does not have to be dangerous to deserve a treatment discussion.[1,2,19]

Weight, glucose, and cholesterol

Vraylar can cause weight gain and metabolic changes. An average change in a short trial does not reveal what will happen to one person over a year. It also does not remove the need to check blood sugar and cholesterol.[1,16]

In the label’s short bipolar-depression studies, 3% taking either 1.5 or 3 mg gained at least 7% of their starting weight, compared with 1% taking placebo. Seven percent is 14 pounds for someone who starts at 200 pounds. Smaller changes can still matter to the person living with them.[1]

Discuss appetite, food access, movement, sleep, and medical risk without blame. A change in weight is not a failure of character. Ask what the team will monitor and what options exist if it becomes a problem.

Sex, hormones, and emotional experience

Pooled trials found generally small effects on prolactin, a hormone that some antipsychotics can raise. That does not mean sexual side effects are impossible. Depression, other medicines, hormones, sleep, and relationships can also affect desire and sexual function.[20]

Tell the prescriber about new sexual problems, unexpected breast discharge, menstrual changes, or feeling emotionally flat. The goal should include being able to think, feel, and take part in life. Being less outwardly upset is not enough if you feel worse inside.

Boxed warnings

The label carries the antipsychotic warning about increased death risk in older adults with dementia-related psychosis. Vraylar is not approved for that use. Its boxed warning also addresses the increased risk of suicidal thoughts and behaviors found with antidepressants in children, adolescents, and young adults. All patients receiving antidepressant treatment need monitoring for worsening mood and suicidality.[1]

These warnings identify serious risks that require a plan. They do not mean that each person will experience them. Report new suicidal thoughts, marked agitation, or a sudden concerning change in behavior promptly. Do not assume every new problem is simply part of getting used to treatment.

Call promptly or seek urgent assessment

New involuntary mouth, tongue, face, or body movements may signal tardive dyskinesia, which can persist. New stiffness, tremor, falls, or swallowing trouble also need assessment. Extreme thirst, frequent urination, or unexplained weakness can signal high blood sugar.[1,2]

Let the clinician know about fever or infection symptoms if you have a history of low white blood cells. Report fainting, major dizziness, or signs of dehydration. Breathing trouble, choking, severe confusion, or collapse requires emergency care, not a routine message.

Get emergency help now

Call 911 for trouble breathing, swelling of the tongue or throat, a seizure, collapse, inability to wake, or immediate danger of self-harm. Fever with severe muscle stiffness and confusion can be neuroleptic malignant syndrome, a rare medical emergency. Do not wait for a scheduled appointment.[1,2]

For a suspected overdose, call Poison Help at 1-800-222-1222 right away; do not wait for symptoms. Use 911 when serious symptoms are present. For suicidal crisis or help staying safe, call or text 988. These services do not replace emergency medical care when someone is in immediate danger.[2,37]

What monitoring should look like

A good follow-up visit asks about both benefit and burden. Before treatment, the team should document the target symptoms and relevant physical health history. That gives later changes a point of comparison.

Weight, blood pressure, glucose or A1c, and lipids are common parts of antipsychotic monitoring. Movement symptoms, sleep, mood, and daily function also matter. The exact schedule depends on age, medical risk, symptoms, and the practice’s chosen guideline.[16]

Ask who will order tests, who will review them, and how you will hear the result. A lab order without a follow-up plan leaves an important job unfinished. Let both your psychiatric and primary-care clinicians know what is being checked.

A CBC, which measures blood cells, is especially relevant when there is a history of low white cells. An ECG, which records heart rhythm, depends on cardiac risks, symptoms, and other medicines. Routine blood testing to measure a cariprazine level is not part of the label’s standard monitoring plan.[1,16]

Vraylar interactions, alcohol, driving, and heat

The liver uses an enzyme called CYP3A4 to process cariprazine. Medicines that strongly or moderately slow that enzyme can raise exposure. Medicines that speed it up can make the overall effect harder to predict. Some combinations require a different dose; CYP3A4-inducing combinations are not recommended in the U.S. label.[1]

Tell every prescriber and pharmacist that you take Vraylar, including when getting a short course of another medicine. Antifungal medicines, certain antibiotics, some seizure medicines, and ritonavir-containing treatments are examples that need a specific interaction check. Bring supplement bottles too; St. John’s wort can interact.[2,42]

Ask about grapefruit rather than assuming normal food means no interaction. European cariprazine patient information specifically advises avoiding grapefruit juice. This is a food precaution, not a reason to apply European dosing rules to a U.S. prescription.[43]

Avoid alcohol and discuss cannabis or other substance use openly. They can complicate symptoms, judgment, and treatment assessment; alcohol can also worsen medication-related impairment. Sharing accurate information helps the team make a safer plan.[19,36]

Do not drive or use dangerous equipment until you know how the medicine affects you. Plan for this before an early shift, a long commute, or work around machinery.[2]

Inland Empire heat deserves practical attention. Antipsychotics can interfere with the body’s ability to manage heat. Plan access to shade, cooling, and fluids, especially with outdoor work. Ask for individualized advice if a heart or kidney condition limits fluids. Confusion or collapse in the heat is an emergency.[1]

Pregnancy, breastfeeding, children, and other health conditions

Pregnancy and postpartum

If you are planning pregnancy or discover you are pregnant, contact your treatment team before changing the medicine. Human pregnancy evidence for cariprazine remains limited. Animal findings raise concerns but cannot tell us the exact human risk. Untreated illness also carries risks, so the decision needs both sides of the story.[17]

Antipsychotic exposure late in pregnancy can be followed by movement, feeding, breathing, or withdrawal-type symptoms in a newborn. Severity varies; some newborns need extended hospital care. Make sure the obstetric and newborn teams know the medication plan. The National Pregnancy Registry for Psychiatric Medications accepts eligible participants and can help build better evidence.[1,17,34]

Breastfeeding information changed in 2026. A small study measured cariprazine and its active metabolites in milk from five women. Estimated infant exposure was low, but two mothers reported infant lethargy; in one case it resolved after the mother’s dose was reduced. This small, uncontrolled study does not establish long-term safety or prove what caused the symptoms.[18]

Discuss infant age, feeding, growth, alertness, maternal stability, and alternative treatments with the care team. An unusually sleepy or poorly feeding baby needs prompt medical attention. A baby who is hard to wake needs emergency assessment; call 911. Do not treat the phrase low milk exposure as a guarantee of safety.[17,18]

Children and adolescents

The newer pediatric approvals used adult efficacy evidence together with pediatric exposure and safety data. That is different from claiming there were large placebo-controlled pediatric efficacy trials for each indication.[3]

Parents should ask how growth, weight, movement, school function, sleep, and mood will be followed. Adolescents should have a chance to describe their experience in their own words. A child becoming quieter does not by itself show recovery.

Older adults and kidney or liver illness

Older adults may be more vulnerable to falls, interactions, and other medical problems. Severe kidney impairment or severe liver impairment are situations where the U.S. label does not recommend Vraylar. A known allergy to cariprazine or its ingredients is a contraindication.[1]

Tell the team about seizures, fainting, heart disease, swallowing problems, dehydration, and low blood-cell counts. A warning, a contraindication, and a need for extra monitoring are different things. Your clinician should explain which applies to you.

Vraylar vs. other options

The useful comparison begins with the diagnosis and treatment phase. There is no best antipsychotic for every person, and equal milligram numbers do not mean equal strength.

These are separate choices, not a ranking. Lurasidone needs a meal of at least 350 calories. Quetiapine can be sedating and has important metabolic considerations. Aripiprazole and brexpiprazole can also cause restlessness. Lumateperone can cause sleepiness and dizziness. Each needs its own risk discussion.[25,26,27,28,29]

Most comparisons among these medicines come from separate trials rather than direct Vraylar-versus-each-alternative studies. Differences in patients, doses, and follow-up can make side-effect percentages look more comparable than they are.

Off-label uses: questions, not a list of promises

Off-label means a use falls outside the FDA-approved label. It can be clinically reasonable, but the strength of evidence varies greatly. Ask what supports the proposed use and what better-studied options were considered.

A small retrospective OCD study followed 13 people receiving cariprazine added to a serotonin reuptake inhibitor. Symptoms improved, but there was no control group. Such a study can suggest a question for a trial; it cannot establish a reliable expected benefit.[21]

Research on anxiety within depression is not the same as proof of treatment for a primary anxiety disorder. A registered cariprazine add-on GAD trial was withdrawn for a strategic decision with no participants enrolled. That record provides neither positive nor negative efficacy results.[23,41]

Uncontrolled studies involving psychosis and cannabis use do not establish that cariprazine treats addiction. This review found insufficient evidence to present it as an established PTSD treatment. It is not approved as a general treatment for ADHD, insomnia, or everyday low motivation.[1,38,44]

Vraylar cost, generic status, and access

Cariprazine is the generic ingredient name. That does not guarantee that a generic product is available at your pharmacy. The FDA has approved generic cariprazine applications, but as of September 30, 2026, the Drugs@FDA database listed every approved generic cariprazine product (from Zydus, Sun Pharma, and Aurobindo) as discontinued, so a generic capsule is unlikely to be available at U.S. pharmacies right now. Ask the pharmacist to check actual availability and your insurance price.[32,33]

Manufacturer savings cards generally require eligible commercial insurance and exclude Medicare, Medicaid, and other government-funded coverage. A separate patient-assistance program may help some people who meet its criteria. Approval and savings are not guaranteed, and terms change.[30,31]

Before leaving the visit, ask what happens if insurance rejects the prescription or a refill is delayed. Contact the office before you run out. A medicine that cannot be obtained consistently needs an access plan as much as a dosing plan.

How families can help without taking over

Ask the person what support feels useful. That may be a ride, a shared calendar, help with a refill, or joining part of a visit. Agree on what observations can be shared and how. Support should preserve the patient’s voice.

Specific observations are more helpful than labels. “You have slept three hours for two nights and do not seem tired” gives more information than “You are acting manic.” “You keep pacing and say your body will not settle” gives more information than “You are being difficult.”

Bring the person’s own goals into the discussion: attending school, enjoying meals, working safely, or feeling able to talk with family. Treatment can reduce symptoms while leaving other needs unmet. Therapy, routines, social support, and practical help still matter.[35,36]

Use a brief weekly record: prescribed dose and missed doses; sleep; one target symptom; one daily task; restlessness or other side effects; and any new medicine or substance. Bring it to follow-up. Severe symptoms should be reported right away instead of saved for the tracker.

A one-page guide for families

Know the purpose. Vraylar can treat schizophrenia, certain bipolar I episodes, or help an antidepressant treat adult major depression. A prescription alone does not tell you the diagnosis. Ask: what are we treating, and what change would matter in daily life?[1]

Watch together, with permission. Notice sleep, one target symptom, one daily task, and side effects. Ask what the person feels, not just whether they seem quieter. New pacing or an inner need to move can be akathisia. Call the prescriber promptly, especially after a dose change. Some effects appear weeks later.[1]

Call the team promptly for new or worsening restlessness, unwanted movements, major sleep changes, falls, trouble swallowing, worsening mood, or side effects that interfere with life. Severe symptoms need urgent assessment.[1,2]

Call 911 for trouble breathing, throat swelling, seizure, collapse, inability to wake, immediate danger of self-harm, or fever with severe stiffness and confusion. For a suspected overdose, call Poison Help at 1-800-222-1222 right away, and use 911 for serious symptoms. For a suicidal crisis or help staying safe, call or text 988.[2,37]

Keep the daily plan simple. Take only the prescribed dose, once daily, with or without food. Do not double a missed dose, and ask for advice after several missed doses. Check new medicines and supplements with the pharmacist. Avoid alcohol. Do not drive until effects are known. Plan cooling and fluids in hot weather. Contact the team before stopping or changing treatment.[1,2,19]

Bring a short weekly record to follow-up: prescribed dose and missed doses, sleep, one target symptom or daily task, and restlessness or other side effects.

Ask before leaving the visit: What benefit are we looking for? When is follow-up? What tests are due? Whom do we call for side effects or a refill problem? What is the plan if treatment helps, or does not?[16]

Ten questions for your next appointment

1. What exact condition and symptoms are we treating?
2. What would count as worthwhile improvement for me?
3. Why does Vraylar fit better than other options we could consider?
4. What is my dose plan, and when will we review it?
5. How can I recognize akathisia, and whom do I call?
6. What monitoring is due, and who reviews the results?
7. Are there interactions with my medicines, supplements, or substances?
8. What should I do after missed doses or a refill delay?
9. How do pregnancy plans, work, driving, or cost affect the choice?
10. If it helps, what is the longer-term plan? If it does not, what comes next?

Frequently asked questions

Is Vraylar an antidepressant?

It belongs to the atypical antipsychotic class. It has an approved role in adult bipolar I depression and, for adult MDD, as an addition to an antidepressant. The class name and treatment purpose are different pieces of information.[1]

Does taking it mean I have schizophrenia?

No. The same medicine has several approved uses. Ask the prescriber to name the diagnosis and target symptoms instead of inferring them from the bottle.[1]

Is it a cure?

It can help control symptoms. A response does not erase the need for follow-up or other parts of care. Treatment goals should include functioning and quality of life, not just a score.[2,35]

Can it treat bipolar II depression?

That is not a current FDA-approved use. The evidence is less established than for bipolar I depression. A proposed off-label use should come with an explanation of the evidence and alternatives.[22]

Can children take it?

Certain pediatric uses are approved: schizophrenia from age 13, and acute bipolar I mania or mixed episodes from age 10. Those approvals do not include pediatric depression.[3]

How soon should I feel better?

Some changes may occur early; fuller benefit can take weeks or longer. Agree on review points for your condition. Do not wait through dangerous deterioration just to reach a planned week count.[2,4]

Can side effects appear later?

Yes. Active metabolites accumulate slowly. Keep watching after dose changes even if the first days feel unchanged.[13]

Does more medicine work better?

Not necessarily. Some trials did not find a larger benefit at higher doses, while adverse effects can increase. Dose changes belong with the prescriber.[7,9]

Is my new anxiety actually akathisia?

It could be, especially if there is a driven need to move after a medication change. Anxiety and other causes are also possible. Describe the feeling and timing so it can be assessed.[16]

Will it cause weight gain?

It can. The amount varies, and early averages do not predict an individual’s long-term experience. Track changes and keep metabolic follow-up.[1]

Will it affect sex or my personality?

No one can promise zero sexual or emotional effects. Report feeling flat, unlike yourself, or less able to function. Those experiences belong in the benefit-versus-burden discussion.[20]

Should I take it at night?

There is no one best time for everyone. Ask about timing if you become sleepy or have trouble sleeping. Follow the once-daily prescription.[2]

What if I miss a dose?

Take it when remembered unless the next dose is almost due. Then skip it. Do not double. Ask for restart advice after a longer gap.[2]

Can I stop when I feel well?

Feeling well is a reason to review the plan. It is not a reason for an unplanned stop. Discuss ongoing need, side effects, relapse risk, and how any change will be monitored.[10,12]

Is it addictive?

It is not a controlled substance. However, formal studies of abuse and physical dependence are limited. A need for a supervised stopping plan is different from addiction.[1]

Can I drink alcohol or use cannabis?

Avoid alcohol and discuss cannabis or other drug use with the team. These can worsen impairment or complicate symptoms and assessment. Do not hide use to avoid an uncomfortable conversation.[19,36]

What if I become pregnant or want to breastfeed?

Contact the team before changing treatment. Pregnancy data are limited, and the new milk study is too small to establish safety. The plan must protect both parent and baby.[17,18]

How will we know whether it is worth continuing?

Review the same targets you chose at the start, alongside side effects, functioning, and cost. Bring your medication list and a short symptom record. A useful visit ends with a clear next step and a way to get help sooner if needed.

Related reading on NP FADY

• Bipolar depression treatment options
• Bipolar mixed features and agitated depression
• Pregnancy and postpartum treatment planning
• Relapse warning signs and planning
• Rexulti (brexpiprazole): uses, side effects, and how it compares with Abilify
• Bipolar and schizophrenia medicines in pregnancy and breastfeeding

Educational disclaimer

This article is for education. It does not diagnose any condition, choose a medication for anyone, or replace the judgment of the clinician who knows your history. Do not start, stop, or change any medication without your prescriber. If there is imminent danger, or you cannot keep yourself or someone else safe, call 911 or go to the nearest emergency department. In the United States, call or text 988, or chat at 988lifeline.org, for any mental-health crisis. For a suspected overdose or accidental ingestion, call Poison Help at 1-800-222-1222. Regulatory and numeric claims in this article were checked against current FDA labeling and primary studies on September 30, 2026. Labels, approvals, and availability change; confirm current status with your prescriber or pharmacist before acting on anything here.

References

1. AbbVie / FDA (revised December 2025). Vraylar prescribing information and Medication Guide. https://www.rxabbvie.com/pdf/vraylar_pi.pdf Accessed 2026-09-30.
2. U.S. National Library of Medicine (revised November 15, 2025). Cariprazine: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a615050.html Accessed 2026-09-30.
3. FDA (2025). Pediatric review and supplemental approval for Vraylar. https://www.fda.gov/media/191103/download Accessed 2026-09-30.
4. Sachs GS et al. (2023). Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. DOI: 10.1176/appi.ajp.20220504. PMID: 36789515. https://pubmed.ncbi.nlm.nih.gov/36789515/ Accessed 2026-09-30.
5. Riesenberg R et al. (2023). Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. DOI: 10.4088/jcp.22m14643. PMID: 37585254. https://pubmed.ncbi.nlm.nih.gov/37585254/ Accessed 2026-09-30.
6. Earley W et al. (2019). Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. DOI: 10.1176/appi.ajp.2018.18070824. PMID: 30845817. https://pubmed.ncbi.nlm.nih.gov/30845817/ Accessed 2026-09-30.
7. Earley WR et al. (2020). Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. DOI: 10.1111/bdi.12852. PMID: 31628698. https://pubmed.ncbi.nlm.nih.gov/31628698/ Accessed 2026-09-30.
8. Durgam S et al. (2014). An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. DOI: 10.1016/j.schres.2013.11.041. PMID: 24412468. https://pubmed.ncbi.nlm.nih.gov/24412468/ Accessed 2026-09-30.
9. Calabrese JR et al. (2015). Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. DOI: 10.4088/jcp.14m09081. PMID: 25562205. https://pubmed.ncbi.nlm.nih.gov/25562205/ Accessed 2026-09-30.
10. Durgam S et al. (2016). Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. DOI: 10.1016/j.schres.2016.06.030. PMID: 27427558. https://pubmed.ncbi.nlm.nih.gov/27427558/ Accessed 2026-09-30.
11. Németh G et al. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. DOI: 10.1016/s0140-6736(17)30060-0. PMID: 28185672. https://pubmed.ncbi.nlm.nih.gov/28185672/ Accessed 2026-09-30.
12. McIntyre RS et al. (2024). Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder. DOI: 10.1111/bdi.13421. PMID: 38609342. https://pubmed.ncbi.nlm.nih.gov/38609342/ Accessed 2026-09-30.
13. Nakamura T et al. (2016). Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). DOI: 10.2147/dddt.s95100. PMID: 26834462. https://pubmed.ncbi.nlm.nih.gov/26834462/ Accessed 2026-09-30.
14. Kiss B et al. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. DOI: 10.1124/jpet.109.160432. PMID: 20093397. https://pubmed.ncbi.nlm.nih.gov/20093397/ Accessed 2026-09-30.
15. Girgis RR et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. DOI: 10.1007/s00213-016-4382-y. PMID: 27525990. https://pubmed.ncbi.nlm.nih.gov/27525990/ Accessed 2026-09-30.
16. American Psychiatric Association (2020). Practice Guideline for the Treatment of Patients With Schizophrenia, third edition. https://www.med.unc.edu/psych/epi-nc/wp-content/uploads/sites/720/2024/01/APA-2020-guidelines-1.pdf Accessed 2026-09-30.
17. MotherToBaby / OTIS (June 2026). Cariprazine (Vraylar). https://mothertobaby.org/fact-sheets/cariprazine-vraylar/ Accessed 2026-09-30.
18. Balamurali S et al. (2026). Cariprazine in Human Milk: Cautionary Implications for Use During Lactation. DOI: 10.1097/jcp.0000000000002174. PMID: 42085651. https://pubmed.ncbi.nlm.nih.gov/42085651/ Accessed 2026-09-30.
19. NAMI / AAPP (2023 handout; accessed 2026). Cariprazine (Vraylar). https://www.nami.org/treatments-and-approaches/mental-health-medications/types-of-medication/cariprazine-vraylar/ Accessed 2026-09-30.
20. Culpepper L et al. (2022). Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. DOI: 10.2147/ndt.s348143. PMID: 35591886. https://pubmed.ncbi.nlm.nih.gov/35591886/ Accessed 2026-09-30.
21. Martiadis V et al. (2024). Serotonin reuptake inhibitors augmentation with cariprazine in patients with treatment-resistant obsessive-compulsive disorder: a retrospective observational study. DOI: 10.1017/s1092852924000348. PMID: 38774970. https://doi.org/10.1017/S1092852924000348 Accessed 2026-09-30.
22. Yatham LN et al. (2020). Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial. DOI: 10.1097/yic.0000000000000307. PMID: 32058426. https://pubmed.ncbi.nlm.nih.gov/32058426/ Accessed 2026-09-30.
23. ClinicalTrials.gov (record updated April 12, 2022; checked 2026). NCT04965272: adjunctive cariprazine in generalized anxiety disorder. https://clinicaltrials.gov/study/NCT04965272 Accessed 2026-09-30.
24. McIntyre RS et al. (2025). Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials. DOI: 10.1007/s12325-024-03009-2. PMID: 39520655. https://pubmed.ncbi.nlm.nih.gov/39520655/ Accessed 2026-09-30.
25. DailyMed / current U.S. labeling (retrieved 2026). CAPLYTA (lumateperone). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5 Accessed 2026-09-30.
26. DailyMed / current U.S. labeling (retrieved 2026). LATUDA (lurasidone). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8 Accessed 2026-09-30.
27. DailyMed / current U.S. labeling (retrieved 2026). REXULTI (brexpiprazole). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850 Accessed 2026-09-30.
28. DailyMed / current U.S. labeling (retrieved 2026). SEROQUEL XR (quetiapine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab959a35-d0ba-4f18-8f2e-6619d88b16e3 Accessed 2026-09-30.
29. DailyMed / current U.S. labeling (retrieved 2026). ABILIFY oral (aripiprazole). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac Accessed 2026-09-30.
30. AbbVie (live page checked 2026). Vraylar savings and support. https://www.vraylar.com/savings Accessed 2026-09-30.
31. AbbVie (live page checked 2026). myAbbVie Assist patient assistance programs. https://www.abbvie.com/patients/patient-support/patient-assistance/available-programs.html Accessed 2026-09-30.
32. FDA (September 9, 2022). Approval letter for Zydus cariprazine capsules, ANDA 213984. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/213984Orig1s000ltr.pdf Accessed 2026-09-30.
33. U.S. Food and Drug Administration, openFDA (queried September 30, 2026). Drugs@FDA application records for cariprazine hydrochloride: ANDA 213984 (Zydus), ANDA 213932 (Sun Pharma), ANDA 213982 (Aurobindo); all products listed as Discontinued. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22CARIPRAZINE%20HYDROCHLORIDE%22&limit=100 Accessed 2026-09-30.
34. Massachusetts General Hospital (live page checked 2026). National Pregnancy Registry for Psychiatric Medications. https://womensmentalhealth.org/research/pregnancyregistry/ Accessed 2026-09-30.
35. National Institute of Mental Health (current page accessed 2026). Schizophrenia. https://www.nimh.nih.gov/health/publications/schizophrenia Accessed 2026-09-30.
36. National Institute of Mental Health (current page accessed 2026). Bipolar Disorder. https://www.nimh.nih.gov/health/publications/bipolar-disorder Accessed 2026-09-30.
37. 988 Suicide & Crisis Lifeline (live page checked 2026). Get help. https://988lifeline.org/ Accessed 2026-09-30.
38. Ntouros E et al. (2026). Cariprazine in First-Episode Psychosis with Comorbid Cannabis Use: A Case Series of Eight Patients from Two Greek Early Intervention Units. Brain Sciences 16(8):787. DOI: 10.3390/brainsci16080787. PMID: 42651098. https://pmc.ncbi.nlm.nih.gov/articles/PMC13510350/ Accessed 2026-09-30.
39. Durgam S et al. (2016). Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. DOI: 10.4088/jcp.15m10070. PMID: 27046309. https://pubmed.ncbi.nlm.nih.gov/27046309/ Accessed 2026-09-30.
40. Durgam S et al. (2016). An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. DOI: 10.1176/appi.ajp.2015.15020164. PMID: 26541814. https://pubmed.ncbi.nlm.nih.gov/26541814/ Accessed 2026-09-30.
41. Strawn JR, Mills JA (2026). Trajectories and predictors of depressive and anxiety symptom improvement with adjunctive cariprazine in antidepressant-treated adults with major depression: A Bayesian mega-analysis of two randomized trials. DOI: 10.1016/j.jad.2025.120657. PMID: 41224012. https://pubmed.ncbi.nlm.nih.gov/41224012/ Accessed 2026-09-30.
42. FDA (current table accessed 2026). Examples of Drugs that Interact with CYP Enzymes and Transporter Systems. https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems Accessed 2026-09-30.
43. European Medicines Agency (product information updated January 8, 2026). Reagila (cariprazine). https://www.ema.europa.eu/en/documents/product-information/reagila-epar-product-information_en.pdf Accessed 2026-09-30.
44. Szerman N et al. (2025; online September 2024). Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. DOI: 10.1097/YIC.0000000000000568. PMID: 39319529. https://pubmed.ncbi.nlm.nih.gov/39319529/ Accessed 2026-09-30.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, or chat at 988lifeline.org, available 24/7, free and confidential. En español: marque 988 y oprima 2, o envíe AYUDA al 988. Deaf or hard of hearing: 988 videophone (ASL) or TTY 711 then 988. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.